DAPHNe试验二次分析:新辅助THP治疗HER2阳性早期乳腺癌的5年结局与ctDNA动态
该研究为DAPHNe单臂2期试验的预设二次分析,评估98例II-III期ERBB2阳性乳腺癌患者接受12周新辅助THP的5年结局及超敏ctDNA动态。中位随访5.2年,5年无事件生存率99%、无复发生存间期98%、远处无复发生存间期100%、总生存率99%。57例ctDNA分析中基线检出率89.5%,新辅助后清除率96.1%,支持ctDNA指导降阶梯策略的进一步研究。
要点
- 12周新辅助THP在II-III期HER2阳性乳腺癌中5年EFS达99%、OS达99%。
- 超敏ctDNA基线检出率89.5%,新辅助后清除率96.1%,术前仅3.9%阳性。
- 术后随访期ctDNA可检出率持续低于10%,支持ctDNA指导降阶梯治疗研究。
核心结论
- 在DAPHNe非随机临床试验的二次分析中,12周新辅助THP与早期ERBB2阳性乳腺癌患者优异的长期结局相关。
- 超敏ctDNA分析显示高基线检出率和缩短新辅助治疗后近乎普遍的清除,支持在该情境下进一步研究ctDNA指导的降阶梯策略。
研究设计与样本
- 本研究为前瞻性、单臂、研究者发起的2期DAPHNe非随机临床试验的预设二次分析。
- 总体试验队列纳入98例II至III期ERBB2阳性乳腺癌患者,接受12周新辅助THP。
- 对具有可用肿瘤组织和连续血浆样本的患者进行超敏ctDNA分析,二次分析于2023年3月至2025年4月进行。
主要发现
- 总体试验队列98例患者中位年龄49.5岁,97例女性(99.0%),1例男性(1.0%),91例(92.9%)为2期,65例(66.3%)为激素受体阳性。
- 中位随访5.2年,5年无事件生存率为99%(95% CI,97%-100%),5年无复发生存间期为98%(95% CI,93%-100%)。
- 5年远处无复发生存间期为100%(95% CI,100%-100%),5年总生存率为99%(95% CI,97%-100%)。
- 57例纳入ctDNA分析的患者中,基线ctDNA检出51例(89.5%);新辅助治疗后49/51例(96.1%)清除,仅2例(3.9%)术前仍阳性。
- 术后随访期ctDNA可检出率持续低于10%;1例局部复发患者复发时检出ctDNA,手术切除后清除。
关键数值与推荐
- 5年无事件生存率99%(95% CI,97%-100%)。
- 5年无复发生存间期98%(95% CI,93%-100%)。
- 5年远处无复发生存间期100%(95% CI,100%-100%)。
- 5年总生存率99%(95% CI,97%-100%)。
- 基线ctDNA检出率89.5%(51/57),新辅助后清除率96.1%(49/51),术前ctDNA阳性率3.9%(2/51)。
临床怎么用
- 12周新辅助THP可作为II-III期ERBB2阳性乳腺癌的缩短新辅助方案,与优异长期结局相关。
- 超敏ctDNA检测在新辅助治疗后显示高清除率,可能有助于识别可降阶梯治疗的患者。
- ctDNA指导的降阶梯策略需进一步前瞻性研究验证,目前尚不推荐常规临床决策。
局限性
- 本研究为单臂非随机试验的二次分析,缺乏对照组。
- ctDNA分析仅纳入57例具有可用肿瘤组织和连续血浆样本的患者,样本量有限。
- 随访时间中位5.2年,更长期结局仍需进一步观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The neoadjuvant combination of paclitaxel, trastuzumab, and pertuzumab (THP) represents a promising abbreviated regimen for early-stage ERBB2-positive breast cancer, but long-term outcomes and the role of ultrasensitive circulating tumor DNA (ctDNA) monitoring remain incompletely defined. OBJECTIVE: To assess 5-year outcomes and characterize ctDNA dynamics with an ultrasensitive assay in patients with ERBB2-positive breast cancer receiving neoadjuvant THP. DESIGN, SETTING, AND PARTICIPANTS: This study was a prespecified secondary analysis of the prospective, single-arm, investigator-initiated phase 2 DAPHNe nonrandomized clinical trial. Patients were enrolled in the DAPHNe trial from November 2018 to January 2020. The trial took place at a multicenter academic cancer center and affiliated community practices. Participants included patients with stage II to III ERBB2-positive breast cancer receiving neoadjuvant THP for 12 weeks. Ultrasensitive ctDNA analyses were performed in patients with available tumor tissue and serial plasma samples. The secondary analysis was conducted between between March 2023 and April 2025. INTERVENTIONS: Neoadjuvant THP administered for 12 weeks, followed by surgery and adjuvant therapy guided by pathologic response. MAIN OUTCOMES AND MEASURES: Main outcomes included 5-year event-free survival, recurrence-free interval (RFI), distant RFI, and overall survival. ctDNA detection and clearance were assessed using a whole-genome-based, tumor-informed ultrasensitive assay at 4 predefined time points (baseline, preoperative, postoperative, and late adjuvant). RESULTS: The overall trial cohort included 98 patients (median [IQR] age, 49.5 years [24.0-78.0 years]; 97 female patients [99.0%]; 1 male patient [1.0%]), with mostly stage 2 disease (91 patients [92.9%]) and hormone receptor-positive tumors (65 patients [66.3%]). With a median (IQR) follow-up of 5.2 (5.0-5.4) years, the 5-year event-free survival was 99% (95% CI, 97%-100%), the 5-year RFI was 98% (95% CI, 93%-100%), the 5-year distant RFI was 100% (95% CI, 100%-100%), and the 5-year overall survival was 99% (95% CI, 97%-100%). Among 57 patients included in ctDNA analyses, baseline ctDNA was detected in 51 individuals (89.5%). After neoadjuvant therapy, ctDNA clearance occurred in 49 of 51 patients (96.1%), with only 2 individuals (3.9%) remaining ctDNA-positive preoperatively; detectability remained low (<10%) during postoperative follow-up. One single patient experienced a local recurrence, with ctDNA detected at time of recurrence and cleared following surgical resection. CONCLUSIONS AND RELEVANCE: In this secondary analysis of the DAPHNe nonrandomized clinical trial, neoadjuvant THP was associated with excellent long-term outcomes in patients with early-stage ERBB2-positive breast cancer. Ultrasensitive ctDNA analyses demonstrated high baseline detection rates and near-universal clearance after abbreviated neoadjuvant therapy, supporting further investigation of ctDNA-guided de-escalation strategies in this setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03716180.
引用
- Tarantino P, Li T, Ogayo ER, et al. Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial. JAMA Oncol. 2026. PMID: 42348190. doi:10.1001/jamaoncol.2026.2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。